Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
CEO: Robert Ford. Company website
Abbott Laboratories (ABT) trades at $102.55, up 0.31% on the day, as of Sep 20, 2026 14:59 UTC.
Abbott Laboratories has a market capitalisation of $177.45B, calculated from the live ABT share price and shares outstanding.
ABT trades at a trailing P/E of 32.97, from earnings per share of $3.11 over the last twelve months.
Abbott Laboratories generated revenue of $46.59B over the trailing twelve months, which puts the stock at 3.81 times sales.
Yes. Abbott Laboratories pays a dividend yielding 1.94% on the current share price.
ABT has traded between $81.97 and $137.49 over the past 52 weeks, and the last price is 25.4% below that high.
Yes. Abbott Laboratories keeps 11.65% of revenue as net income over the trailing twelve months.
Wall Street analysts rate ABT Buy, with an average price target of $121.50, 18.5% above the current price.
Abbott Laboratories is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Robert Ford is the chief executive of Abbott Laboratories, which employs 115,000 people.
QFI Terminal shows ABT with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ABT in Terminal See plans